Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Hepatocellular Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(284)
News
Trials
Search handles
@ArndtVogel
@DenboJw
@DrBonillaOnc
@DrSukeshiArora
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@ESchattner
@FernandoOnco
@FogacciJoao
@GABOUALFA
@GIcancerDoc
@GillSharlene
@HHorinouchi
@JDekervel
@LorenzaRimassa
@MadisonConces
@MarkYarchoan
@OmidHamidMD
@PTarantinoMD
@SKamath_MD
@StephenVLiu
@SuyogCancer
@SyedAAhmad5
@VivekSubbiah
@anita_turk
@antonyruggeri
@carlosbon78
@dr_yakupergun
@freddyeescorcia
@kmody29
@medoncdoc
@mtmdphd
@pashtoonkasi
@rachnatshroff
@rcarvalhoonco
Search handles
@ArndtVogel
@DenboJw
@DrBonillaOnc
@DrSukeshiArora
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@ESchattner
@FernandoOnco
@FogacciJoao
@GABOUALFA
@GIcancerDoc
@GillSharlene
@HHorinouchi
@JDekervel
@LorenzaRimassa
@MadisonConces
@MarkYarchoan
@OmidHamidMD
@PTarantinoMD
@SKamath_MD
@StephenVLiu
@SuyogCancer
@SyedAAhmad5
@VivekSubbiah
@anita_turk
@antonyruggeri
@carlosbon78
@dr_yakupergun
@freddyeescorcia
@kmody29
@medoncdoc
@mtmdphd
@pashtoonkasi
@rachnatshroff
@rcarvalhoonco
Filter by
Latest
9ms
🎥@GABOUALFA (@MSKCancerCenter) highlights exciting anti-TIGIT therapies for hepatocellular carcinoma. Promising results from MORPHEUS-Liver trial with tiragolumab, atezolizumab, and bevacizumab: ➡️https://t.co/hR1dCQJTBi⬅️ #ASCO23 #Oncology #ImmunoOnc (@VJOncology)
9 months ago
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)
9ms
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in HCC @OncologyAdvance https://t.co/xit1v39BjF ❓What should we do and what can we expect for 2nd line therapy 🌍RWD suggest: 👉AtzeBev > Lenva 👉Lenva > ICI @myESMO @ILCAnews @EASLedu… https://t.co/ALX315Novm (@ArndtVogel)
9 months ago
Clinical
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • Lenvima (lenvatinib)
9ms
👏👏@KWegermann and @CindyMoylan_MD shared their valuable insights on the main challenges and barriers in #HCC surveillance for patients with #NAFLD in the podcast with our cooperated @ILCAnews 👉Welcome to listen full podcast: https://t.co/THK8488CYU (@HepatomaRes)
9 months ago
Clinical
9ms
Check out our recent research study on hepatic adenoma subtypes and their imaging findings at gadoxetate disodium-enhanced MRI! @StanfordRad @StanfordBodyRad @RadiologyUcla @StevenSRaman_MD (@justintsemd)
9 months ago
9ms
Is it possible to eliminate hepatitis C as a public health threat by 2030? We have #Cure for #elimination of #HCV and reduce #LiverCancer #EUCancerPlan #WorldHepatitisDay @EU_Health @SKyriakidesEU @WHO_Europe @hans_kluge @AleksanderKrag @EASLEUAffairs @EASLedu @Marko_Korenjak (@EuropeLiver)
9 months ago
9ms
#LIRADS and #OPTN teams discussing incorporating #CEUS as an approved modality for #liver #transplant #HCC exception point allocation - coming in 2024! @chemshift1 @YKono (@VChernyakMD)
9 months ago
9ms
Resection for multifocal HCC? Only the exceptional case. It will be interesting to see how adjuvant atezo/bev changes practice. Of note, 90% of patients enrolled in the trial had a solitary HCC. https://t.co/C8mZkmJ5Rs. (@DenboJw)
9 months ago
Clinical
|
Avastin (bevacizumab) • Tecentriq (atezolizumab)
10ms
It was a complete honor and privilege speaking about the things I’m most passionate about with you @thehowie and @hmkyale ! Lots of work is left to be done for patients with #LiverCancer (@JuliusChapiro)
10 months ago
Clinical
10ms
Systematic review & meta-analysis examines hepatocellular carcinoma incidence after sustained virologic response with direct-acting antivirals. Read the article here ➡️https://t.co/MCly5Qb3UJ @nje_kim @gnioannou @CraveroAnnie @ErinClevelandMD (@AGA_CGH)
10 months ago
Retrospective data • Review
10ms
Absolutely! Join us in San Antonio for a comprehensive liver cancer (HCC, CCA, CRCLM, & more) conference with fantastic experts! +CME and CNE included @AlexParikhMD @VautheyMD @ColinCourtMD @sepideh_gholami @AdamYopp @UTHealthSAMDA @UTHealthSA @UnivHealthSA @UnivTransplant (@DrSukeshiArora)
10 months ago
CME
10ms
Update your clinical rulebook for #HepatocellularCarcinoma! Ensure it is renovated and up to date with Drs. @GABOUALFA, @docamitgs, Lipika Goyal, & Ahmed Omar Kaseb with this #MedEd activity developed with @PeerView that was taken from #ASCO23: https://t.co/gnllXyrYEK #HCC (@BlueFaeryLiver)
10 months ago
Clinical
10ms
At #ILCA23, you will explore new frontiers for immunotherapy in hepatocellular carcinoma. @MarkYarchoan - coming directly from the US -will discuss predictive biomarkers for immunotherapy in #HCC and review data from completed clinical trials and work from neoadjuvant clinical… https://t.co/4UvgPtHFCX (@ILCAnews)
10 months ago
Clinical • Review • IO biomarker
10ms
How current is your clinical rulebook for #HepatocellularCarcinoma? Make sure it's renovated and up to date with Drs. @GABOUALFA, @docamitgs, Lipika Goyal, and Ahmed Omar Kaseb! Produced with @BlueFaeryLiver: https://t.co/2swCtC4YxF #ASCO23 #HCC #MedEd #MedTwitter (@PeerView)
10 months ago
Clinical
10ms
Let’s discuss #HCC with experts!Diagnosing Patients With Hepatocellular Carcinoma @GABOUALFA @mdmanishshah https://t.co/2CQTDBn5Nt via @onclive @UAZCancer (@rachnatshroff)
10 months ago
Clinical
10ms
At #ILCA23, you will explore new frontiers for immunotherapy in hepatocellular carcinoma. @MarkYarchoan - coming directly from Sidney -will discuss predictive biomarkers for immunotherapy in #HCC and review data from completed clinical trials and work from neoadjuvant clinical… https://t.co/a8bhCH7tdS (@ILCAnews)
10 months ago
Clinical • Review • IO biomarker
10ms
Exciting news! Dr. Hashem El-Serag (@SeragHashem) & Dr. Cheryl Walker were awarded the Helis Medical Research Foundation grant. 🎉 Their study, "Identification of an Epigenetic Risk Network for Hepatocellular Carcinoma," aims to make strides in understanding liver cancer.#BCMDoM (@BCMDeptMedicine)
10 months ago
Grant
10ms
Reverse the first one you are hit with, NAFLD or T2DM to avoid #LiverCancer (@Pro_Bharati)
10 months ago
10ms
Excited to see this published: Current Landscape of Therapies for Hepatocellular Carcinoma https://t.co/N1GghEv9a1 @TimGreten grateful to @coffman_kelley @changqingxie @ShadinGhabra_MD @donnamabry @NCIResearchCtr @theNCI @NCICCR_MOS (@CeciliaMonge4)
10 months ago
10ms
Sequential chemotherapy and radiofrequency ablation is a good treatment strategy to select the best candidates for surgical treatment among patients with #pancreaticcancer with oligo-hepatic metastasis Do you agree?🧐 🔗https://t.co/gqJwgQ865h #TJ🔖 @Aiims1742 (@TumoriJ)
10 months ago
Clinical
10ms
Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2023 Las Vegas, NV US November 10, 2023 to November 11, 2023 Via @MayoMedEd (Thanks for the heads-up @MiteshBorad!) #hpbcsm #cholangiocarcinoma #biliarytractcancer #bileductcancer #gioncology https://t.co/iP2LnFZUQz (@ccadigest)
10 months ago
10ms
Addressing viral #hepatitis B, D and C to reduce the incidence of #livercancer should be considered in all the cancer prevention initiatives mentioned in the Europe Beating Cancer Plan #EUCancerPlan @EU_Health #WorldHepatitisDay @SKyriakidesEU @hans_kluge @WHO_Europe @EASLnews (@EuropeLiver)
10 months ago
10ms
🎥@ArndtVogel discusses the latest developments in FGFR inhibition in hepatobiliary cancer. Pemigatinib and futibatinib show promise in cholangiocarcinoma, and RLY-4008 offers reduced toxicity: ➡️https://t.co/Fk9WqYbQcp⬅️ #WCGIC23 @myESMO #HPBCsm (@VJOncology)
10 months ago
Lytgobi (futibatinib) • Pemazyre (pemigatinib) • lirafugratinib (RLY-4008)
10ms
A new perspective on management of #HCC now online on @TheLancetOncol by HCC Special interest group of Italian Association for study of liver disease @AisfFegato @Vaital73 @cabibbo78 @FRPonziani @LaiQuirino @DJPinato @casadei_gardini @CiroCelsa @prof_cillo https://t.co/wMv05I2sKm (@PROMISEUnipaHCC)
10 months ago
10ms
#Tcells T cells #leukemia #leukaemia #cancer #autoimmune #autoimmunity #immunotherapy #bladdercancer stomach cancer #braincancer #breastcancer #midwifery #childhoodcancer uterine cancer #coloncancer #kidneycancer #livercancer #lymphoma #myeloma pancreatic cancer #ovariancancer (@SilkeLeFay)
10 months ago
Clinical
10ms
Among people w/ #NAFLD, the presence of type 2 #diabetes is associated w/ a significantly ⬆️ risk of hepatic decompensation & hepatocellular carcinoma after adjusting for age, BMI, race, & baseline liver stiffness #LiverTwitter #OncTwitter @OncoAlert #HCC @DrHuangDQ @DrLoomba (@Rob__Brierley)
10 months ago
10ms
Very interesting! With 14% of HCC in patients without cirrhosis and an incidence over 2 per 1000 years, wouldn't this argue for HCC screening prior to diagnosis of cirrhosis? (@liverazzi)
10 months ago
Clinical
10ms
A different point of view in HCC management by the HCC Special Interest Group of the Italian Association for the Study of the Liver. The role of the multidisciplinary tumor board. @Vaital73 @FRPonziani @LaiQuirino @DJPinato @casadei_gardini @CiroCelsa @prof_cillo @AisfFegato (@cabibbo78)
10 months ago
10ms
¡ɔɔɥ ɟo ʇuǝɯǝƃɐuɐɯ ǝɥʇ uı ʍǝıʌ ɟo ʇuıod ʍǝu ɐ ǝsodoɹd ǝʍ Personalised management of patients with hepatocellular carcinoma: a m... https://t.co/U7xhvCKUmE @Vaital73 @cabibbo78 @FRPonziani @LaiQuirino @DJPinato @casadei_gardini @CiroCelsa @prof_cillo #HCC #livertwitter (@massimoiava)
10 months ago
Clinical
10ms
🎥@GABOUALFA of @MSKCancerCenter discusses locoregional vs. systemic treatment in hepatocellular carcinoma. Exciting findings from EMERALD-3 trial show promise for immunotherapy! ➡️https://t.co/5NZ47yB5mp⬅️ #ASCO23 #ImmunoOnc ##HPBCsm (@VJOncology)
10 months ago
10ms
Is regular statin intake associated with a reduced rate of new liver diseases and liver-related death in the general population? Our recent work published in JAMA Network Open @DrLoomba @C_V_Schneider #livertwitter #HCC #Liver https://t.co/pYYKKeX59H (@DrAKrishnanMD)
10 months ago
Clinical
10ms
How does diabetes influence outcomes in NAFLD? ▶️>2000 participants with NAFLD characterized by MR elastography DM a/w ⬆️risk of decompensation and #HCC ❗️Independent of baseline liver stiffness New data @_NAFLDResearch @DrLoomba @LancetGastroHep https://t.co/ryC7nkRIjV (@DrHuangDQ)
10 months ago
10ms
⚠️T2 diabetes is associated with a higher risk of hepatic decompensation and hepatocellular carcinoma in NAFLD. Our new paper in @LancetGastroHep, led by @DrLoomba and @DrHuangDQ, is now available online. (@DrMaralMD)
10 months ago
10ms
This is a very interesting question… if most patients at this age die from cardiovascular or extrahepatic neoplasias… we should think twice before taking a decision (@gui_cancado)
10 months ago
Clinical
10ms
#Hepatitis B is a viral infection that affects the liver and can lead to serious complications, including #livercancer and #livercirrhosis. @AleksanderKrag @EU_Health @SKyriakidesEU @hans_kluge #WorldHepatitisDay #EUCancerPlan @Marko_Korenjak @EASLEUAffairs @WHO_Europe (@EuropeLiver)
10 months ago
Clinical
10ms
Great to speak with @JDekervel of @KU_Leuven today on the benefits & drawbacks of total neoadjuvant therapy, individualizing treatment approaches for advanced HCC, and more! @myESMO #WCGIC2023 #GIsm #GastrointestinalCancer (@VJOncology)
10 months ago
Clinical • Metastases
10ms
Metastatic hepatoma (@neilvanrijn)
10 months ago
Metastases
10ms
Editorial - Untangling the web of waitlist dropout in hepatocellular carcinoma by @laurakulik1 of @Nmliver https://t.co/GIq5JYVUs6 #HCC #livertwitter (@LTxJournal)
10 months ago
10ms
4-years OS update from HIMALAYA ph-3 trial in unresectable hepatocellular carcinoma. STRIDE regimen (Tremelimumab + Durvalumab) maintains significant long-term OS benefit vs sorafenib. At 4 years, 1/4 of the patients in the STRIDE arm remained alive. Very good results! #WCGIC2023 (@carlosbon78)
10 months ago
Clinical
|
Imfinzi (durvalumab) • sorafenib • Imjudo (tremelimumab)
10ms
4-yr OS update from the phs 3 HIMALAYA trial of tremelimumab + durvalumab in HCC at #WCGIC2023 👉Excellent long-term survival data for STRIDE 👉4-yr OS rate of 19% (unprecedented in HCC) 👉Long-term OS observed in relevant subgroups, incl. pts with non-viral liver disease… https://t.co/ZTzq8PM6je (@ArndtVogel)
10 months ago
Clinical
|
Imfinzi (durvalumab) • Imjudo (tremelimumab)
10ms
Radioembolization for Intermediate-Stage Hepatocellular Carcinoma Maintains Liver Function and Permits Systemic Therapy at Progression https://t.co/ejEVNmsmCq Fig: Kaplan-Meier curve showing overall survival on intention-to-treat basis @kush_r_desai @riadsalemIR (@JVIRmedia)
10 months ago
Clinical
10ms
Amit Singal, MD, on next steps after diagnosing a patient with metastatic hepatocellular carcinoma. #HCC | @docamitgs @utswcancer https://t.co/ErsheIeKnR (@TargetedOnc)
10 months ago
Clinical • Metastases
10ms
Potentially revolutionary treatment targets in #Fibroblasts #HCC #HepatocellularCarcinoma #Cholangiocarcinoma #LiverTwitter #OncTwitter @OncoAlert @LancetGastroHep @Rob__Brierley @RashidLui @StephenLChan1 (@wonglaihung)
10 months ago
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login